Latest Stocks: ValuEngine Downgrades Alcobra Ltd (ADHD) to Strong Sell

Latest Stocks: ValuEngine Downgrades Alcobra Ltd (ADHD) to Strong Sell

Alcobra Ltd (NASDAQ:ADHD) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Friday.

ADHD has been the topic of several other research reports. Roth Capital set a $4.00 target price on Alcobra and gave the company a “buy” rating in a report on Wednesday, May 31st. Jefferies Group LLC reissued a “hold” rating and issued a $1.25 target price on shares of Alcobra in a report on Friday, March 31st. Zacks Investment Research lowered Alcobra from a “buy” rating to a “hold” rating in a report on Tuesday, March 7th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $1.00 target price on shares of Alcobra in a report on Tuesday, March 28th. Two analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $1.93.

Alcobra (NASDAQ:ADHD) opened at 1.14 on Friday. The company’s 50-day moving average price is $1.16 and its 200 day moving average price is $1.42. The stock’s market capitalization is $31.42 million. Alcobra has a 52 week low of $0.83 and a 52 week high of $5.71.

Alcobra (NASDAQ:ADHD) last posted its earnings results on Tuesday, May 30th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02. Equities research analysts expect that Alcobra will post ($0.64) EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. Knoll Capital Management LP purchased a new position in shares of Alcobra during the third quarter valued at about $2,799,000. Franklin Resources Inc. raised its position in shares of Alcobra by 12.8% in the fourth quarter. Franklin Resources Inc. now owns 4,477,500 shares of the biotechnology company’s stock valued at $9,403,000 after buying an additional 509,065 shares during the last quarter. Royce & Associates LP raised its position in shares of Alcobra by 367.2% in the fourth quarter. Royce & Associates LP now owns 645,055 shares of the biotechnology company’s stock valued at $1,355,000 after buying an additional 507,000 shares during the last quarter. Morgan Stanley raised its position in shares of Alcobra by 3,267.0% in the first quarter. Morgan Stanley now owns 472,495 shares of the biotechnology company’s stock valued at $539,000 after buying an additional 458,462 shares during the last quarter. Finally, J. Goldman & Co LP purchased a new position in shares of Alcobra during the fourth quarter valued at about $546,000. 63.20% of the stock is currently owned by institutional investors.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Related posts

Leave a Comment